The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Failure of Natalizumab to Prevent Relapses in Neuromyelitis Optica
Open accessAbstract
OBJECTIVE: To describe first experiences with the integrin inhibitor natalizumab, given to patients with suspected relapsing-remitting multiple sclerosis (MS) who were later diagnosed with aquaporin 4-positive neuromyelitis optica (NMO). DESIGN: Retrospective case series. SETTING: Neurology departments at tertiary referral centers in Germany. PATIENTS: Patients with NMO who tested positive for antibodies to aquaporin 4. INTERVENTION: Treatment with natalizumab. MAIN OUTCOME MEASURES: Relapses and accumulation of disability. RESULTS: We identified 5 patients (4 female; median age, 45 years) who were initially diagnosed with MS and treated with natalizumab before diagnosis of NMO was established. Natalizumab was given as escalation therapy after failure of first- or second-line immunomodulatory therapies for MS. During natalizumab therapy (median duration, 8 infusions; range, 2-11 infusions), all 5 patients displayed persisting disease activity; a total of 9 relapses occurred (median duration to relapse, 120 days; range, 45-230 days) after the start of treatment. Four patients had an accumulation of disability and 1 patient died 2 months after cessation of natalizumab treatment. CONCLUSIONS: Our results suggest that natalizumab fails to control disease activity in patients with NMO. Neuromyelitis optica should be considered as a differential diagnosis in patients with suspected MS who are unresponsive to natalizumab therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria
Polman, C. H., Reingold, S. C., Banwell, B., Clanet, M., Cohen, J. A., Filippi, M., Fujihara, K., Havrdova, E., Hutchinson, M., Kappos, L., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22366 · Cited by 9,802
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
Polman, C. H., Reingold, S. C., Edan, G., Filippi, M., Hartung, H., Kappos, L., Lublin, F. D., Metz, L. M., McFarland, H. F., O'Connor, P. W., et al. (2005) · Annals of Neurology · doi:10.1002/ana.20703 · Cited by 5,017
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
Polman, C. H., O'Connor, P. W., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D. H., Phillips, J. T., Lublin, F. D., Giovannoni, G., Wajgt, A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044397 · Cited by 3,386
Revised diagnostic criteria for neuromyelitis optica
Wingerchuk, D. M., Lennon, V. A., Pittock, S. J., Lucchinetti, C. F., & Weinshenker, B. G. (2006) · Neurology · doi:10.1212/01.wnl.0000216139.44259.74 · Cited by 2,574
IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel
Lennon, V. A., Kryzer, T. J., Pittock, S. J., Verkman, A. S., & Hinson, S. R. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050304 · Cited by 2,288
The clinical course of neuromyelitis optica (Devic’s syndrome)
Wingerchuk, D. M., Hogancamp, W. F., O’Brien, P. C., & Weinshenker, B. G. (1999) · Neurology · doi:10.1212/wnl.53.5.1107 · Cited by 1,822
Barkhof, F. (1997) · Brain · doi:10.1093/brain/120.11.2059 · Cited by 1,251
Neuromyelitis Optica Brain Lesions Localized at Sites of High Aquaporin 4 Expression
Pittock, S. J., Weinshenker, B. G., Lucchinetti, C. F., Wingerchuk, D. M., Corboy, J. R., & Lennon, V. A. (2006) · Archives of Neurology · doi:10.1001/archneur.63.7.964 · Cited by 701
Brain Abnormalities in Neuromyelitis Optica
Pittock, S. J., Lennon, V. A., Krecke, K., Wingerchuk, D. M., Lucchinetti, C. F., & Weinshenker, B. G. (2006) · Archives of Neurology · doi:10.1001/archneur.63.3.390 · Cited by 675
Cited by
International consensus diagnostic criteria for neuromyelitis optica spectrum disorders
Wingerchuk, D. M., Banwell, B., Bennett, J. L., Cabre, P., Carroll, W., Chitnis, T., de Seze, J., Fujihara, K., Greenberg, B., Jacob, A., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001729 · Cited by 4,649
Neuromyelitis Optica Study Group (NEMOS), Trebst, C., Jarius, S., Berthele, A., Paul, F., Schippling, S., Wildemann, B., Borisow, N., Kleiter, I., Aktas, O., et al. (2014) · Journal of Neurology · doi:10.1007/s00415-013-7169-7 · Cited by 595
Self-citationRamanathan, S., Prelog, K., Barnes, E. H., Tantsis, E. M., Reddel, S. W., Henderson, A. P., Vucic, S., Gorman, M. P., Benson, L. A., Alper, G., et al. (2016) · Multiple Sclerosis Journal · doi:10.1177/1352458515593406 · Cited by 384
Neurodegeneration in multiple sclerosis and neuromyelitis optica
Kawachi, I., & Lassmann, H. (2017) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2016-313300 · Cited by 283
Treatment of neuromyelitis optica: state-of-the-art and emerging therapies
Papadopoulos, M. C., Bennett, J. L., & Verkman, A. S. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.141 · Cited by 262
Metadata
- Authors
- Kleiter, I.
- Venue
- Archives of Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2012-02-01
- Volume
- 69
- Issue
- 2
- Pages
- 239
- ISSN
- 0003-9942 (ISSN-L)
- OpenAlex
- W2079409038
- Cited by
- 294
- References
- 40
- FWCI
- 22.03
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Failure of Natalizumab to Prevent Relapses in Neuromyelitis Optica. https://app.cochat.ai/papers/10.1001/archneurol.2011.216
- The paper
- Kleiter, I. (2012). Failure of Natalizumab to Prevent Relapses in Neuromyelitis Optica. Archives of Neurology. https://doi.org/10.1001/archneurol.2011.216
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
